Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma.

Oncoscience Pub Date : 2023-09-20 eCollection Date: 2023-01-01 DOI:10.18632/oncoscience.587
Mohamed A Gouda, Maria A Zarzour, Ara A Vaporciyan, Kalevi Kairemo, Hubert H Chuang, Vivek Subbiah
{"title":"Activity of pazopanib in <i>EWSR1-NFATC2</i> translocation-associated bone sarcoma.","authors":"Mohamed A Gouda,&nbsp;Maria A Zarzour,&nbsp;Ara A Vaporciyan,&nbsp;Kalevi Kairemo,&nbsp;Hubert H Chuang,&nbsp;Vivek Subbiah","doi":"10.18632/oncoscience.587","DOIUrl":null,"url":null,"abstract":"<p><p>Pazopanib is a multi-kinase inhibitor that is currently approved for treatment of advanced renal cell carcinoma and chemotherapy-refractory soft tissue sarcoma. In this case report, we discuss the case of a patient with a <i>EWSR1-NFATC2</i> fusion positive bone sarcoma who had exceptional tumor control through using pazopanib and surgery for an overall duration exceeding 5 years. We also review the literature on <i>EWSR1-NFATC2</i> translocation-associated sarcomas and use of pazopanib in bone sarcomas.</p>","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"10 ","pages":"44-53"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511123/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18632/oncoscience.587","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Pazopanib is a multi-kinase inhibitor that is currently approved for treatment of advanced renal cell carcinoma and chemotherapy-refractory soft tissue sarcoma. In this case report, we discuss the case of a patient with a EWSR1-NFATC2 fusion positive bone sarcoma who had exceptional tumor control through using pazopanib and surgery for an overall duration exceeding 5 years. We also review the literature on EWSR1-NFATC2 translocation-associated sarcomas and use of pazopanib in bone sarcomas.

Abstract Image

帕唑帕尼在EWSR1-NFATC2易位相关骨肉瘤中的活性。
帕唑帕尼是一种多激酶抑制剂,目前已被批准用于治疗晚期肾细胞癌和化疗难治性软组织肉瘤。在本病例报告中,我们讨论了一名EWSR1-NFATC2融合阳性骨肉瘤患者的病例,该患者通过使用帕唑帕尼和手术获得了特殊的肿瘤控制,总持续时间超过5年。我们还回顾了EWSR1-NFATC2易位相关肉瘤的文献以及帕唑帕尼在骨肉瘤中的应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信